Modern opportunities and prospects for studying pathogenesis, diagnosing and treating hereditary optic neuropathies

doi:https://doi.org/

Close metadata

Abstract:

Objective - to evaluate modern opportunities and prospects for studying pathogenesis and improving diagnostics and treatment of hereditary optic neuropathies (HON). Material and methods. The article presents summarized data on the pathogenesis, diagnostics, and treatment of HON based on modern methods of assessment. Results. The results of long-term worldwide studies and those performed in the Research Institute of Eye Diseases in collaboration with several other institutions are presented. Genetic testing for mitochondrial and nucleus DNA mutations that have a known association with Leber's hereditary optic neuropathy (LHON) and autosomal dominant optic neuropathy (ADON) allow verification only in half of the cases. Particular features of hereditary diseases, such as incomplete penentrance, variable expression, clinical polymorphism, difficulties in detection of hereditary sings, and genetic heterogeneity, are shown to complicate the diagnosis of HON. Spectral retinal tomography revealed characteristic morphometric changes in the macular region and peripapillary nerve fiber layer in the acute stage of LHON. Hereditary optic neuropathies result from a genetically determined decrease in mitochondrial respiratory chain complexes activity, which is associated with a decrease in ATP production. From that standpoint, studying of mitochondrial oxidative phosphorylation biochemical defects in LHON and ADON is an option for detection of mitochondrial dysfunction. Results of a newly proposed method of mitochondrial membrane potential assessment in skin fibroblasts, which can be used for differential diagnosis of mitochondrial optic nerve diseases, are presented. Possible therapeutic measures for HON are discussed. Conclusion. In the prevailing number of cases the described clinical, molecular genetic, and cytological methods ensure proper diagnosis of hereditary optic neuropathies. Prospects of HON treatment, rather ambiguous, are associated with further studying of pathogenesis, development of drugs and gene therapy.

Keywords:

heredetary optic neuropathies

autosomal dominant optic neuropathy

Leber's optic neuropathy

Close metadata

References:

Kerrison J.B. Hereditary optic neuropathies. Ophthalmol. Clin. North Am. 2001; 14: 99-107.
Man P.Y., Griffiths P.G., Brown D.T., Howell N., Turnbull D.M., Chinnery P.F. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am. J. Hum. Genet. 2003; 72: 333-339.
Schaefer A.M., McFarland R., Blakely E.L., He L., Whittaker R.G., Taylor R.W., Chinnery P.F., Turnbull D.M. Prevalence of mitochondrial DNA disease in adults. Ann. Neurol. 2008; 63: 35-39.
Yu-Wai-Man P., Griffiths P.G., Hudson G., Chinnery P.F. Inherited mitochondrial optic neuropathies. J. Med. Genet. 2009; 46: 145-158.
Spruijt L., Kolbach D.N., de Coo R.F., Plomp A.S., Bauer N.J., Smeets H.J., de Die-Smulders C.E.M. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am. J. Ophthalmol. 2006; 141: 676-682.
Puomila A., Hamalainen P., Kivioja S., Savontaus M.L., Koivumaki S., Huoponen K., Nikoskelainen E. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. Eur. J. Hum. Genet. 2007; 15: 1079-1089.
Mackey D.A., Buttery R.G. Leber hereditary optic neuropathy in Australia. Aust. N. Z. J. Ophthalmol. 1992; 20: 177-184.
Yu-Wai-Man P., Griffiths P.G., Burke A., Sellar P.W., Clarke M.P., Gnanaraj L. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology. 2010; 117: 1538.
Toomes C., Marchbank N.J., Mackey D.A., Craig J.E., Newbury-Ecob R.A., Bennett C.P. Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy. Hum. Mol. Genet. 2001; 10: 1369-1378.
Sadun A.A., La Morgia C., Carelli V. Leber's Hereditary Optic Neuropathy. Curr. Treat. Options Neurol. 2011; 13 (1): 109-117.
Kirkman M.A., Yu-Wai-Man P., Korsten A. et al. Gene environment interactions in Leber hereditary optic neuropathy. Brain. 2009; 132: 2317-2326.
Cohn A.C., Toomes C., Potter C., Towns K.V., Hewitt A.W., Inglehearn C.F., Craig J.E., Mackey D.A. Autosomal dominant optic atrophy: penetrance and expressivity in patients with OPA1 mutations. Am. J. Ophthalmol. 2007; 143: 656-662.
Brown M.D., Voljavec A.S., Lott M.T., Torroni A., Yang C.C., Wallace D.C. Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics. 1992; 130: 163-173.
http://www.mitomap.org/bin/view.pl/MITOMAP/MutationsLHON
Yu-Wai-Man P., Votruba M., Moore A.T., Chinnery P.F. Treatment strategies for inherited optic neuropathies: past, present and future. Eye (Lond). 2014; 28 (5): 521-537.
Achilli A., Iommarini L., Olivieri A., Pala M., Hooshiar Kashani B., Reynier P., La Morgia C., Valentino M.L., Liguori R., Pizza F., Barboni P., Sadun F., De Negri A.M., Zeviani M., Dollfus H., Moulignier A., Ducos G., Orssaud C., Bonneau D., Procaccio V., Leo-Kottler B., Fauser S., Wissinger B., Amati-Bonneau P., Torroni A., Carelli V. Rare primary mitochondrial DNA mutations and probable synergistic variants in Leber's hereditary optic neuropathy. PLoS One. 2012; 7 (8): e42242. doi: 10.1371/journal.pone.0042242. Epub 2012 Aug 3.
Ruiz-Pesini E., Lott M.T., Procaccio V., Poole J.C., Brandon M.C., Mishmar D., Yi C., Kreuziger J., Baldi P., Wallace D.C. An enhanced MITOMAP with a global mtDNA mutational phylogeny. Nucleic Acids Res. 2007; 35: 823-828.
Delettre C., Lenaers G., Griffoin J.M., Gigarel N., Lorenzo C., Belenguer P., Pelloquin L., Grosgeorge J., Turc-Carel C., Perret E., starie-Dequeker C., Lasquellec L., Arnaud B., Ducommun B., Kaplan J., Hamel C.P. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat. Genet. 2000; 26: 207-210.
Thiselton D.L., Alexander C., Taanman J.W., Brooks S., Rosenberg T., Eiberg H., Andreasson S., Van R.N., Munier F.L., Moore A.T., Bhattacharya S.S., Votruba M. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. Invest. Ophthalmol. Vis. Sci. 2002; 43: 1715-1724.
Ferre M., Bonneau D., Milea D., Chevrollier A., Verny C., Dollfus H., Ayuso C., Defoort S., Vignal C., Zanlonghi X., Charlin J.F., Kaplan J., Odent S., Hamel C.P., Procaccio V., Reynier P., mati-Bonneau P. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum. Mutat. 2009; 30: 692-705.
Kerrison J.B., Arnould V.J., Ferraz Sallum J.M., Vagefi M.R., Barmada M.M., Li Y., Zhu D., Maumenee I.H. Genetic heterogeneity of dominant optic atrophy, Kjer type: Identification of a second locus on chromosome 18q12.2-12.3. Arch. Ophthalmol. 1999; 117: 805-810.
Barbet F., Hakiki S., Orssaud C., Gerber S., Perrault I., Hanein S., Ducroq D., Dufier J.L., Munnich A., Kaplan J., Rozet J.M. A third locus for dominant optic atrophy on chromosome 22q. J. Med. Genet. 2005; 42: e1.
Carelli V., Schimpf S., Fuhrmann N., Valentino M.L., Zanna C., Iommarini L., Papke M., Schaich S., Tippmann S., Baumann B. et al. A clinically complex form of dominant optic atrophy (OPA8) maps on chromosome 16. Hum. Mol. Genet. 2011; 20 (10): 1893-1905.
Almind G.J., Gronskov K., Milea D., Larsen M., Brondum-Nielsen K., Ek J. Genomic deletions in OPA1 in Danish patients with autosomal dominant optic atrophy. BMC Med. Genet. 2011; 12: 49.
Avetisov SE, Sheremet NL, Vorob'eva OK, Eliseeva EG, Chukhrova AL, Loginova AN, Khanakova NA, Poliakov AV. Clinical and molecular genetic analysis of hereditary optic neuropathies. Vestnik oftal'mologii. 2013;129(2):8-13. (In Russ.)
Carelli V., Ross-Cisneros F.N., Sadun A.A. Mitochondrial dysfunction as a cause of optic neuropathies. Prog. Retin. Eye Res. 2004; 23: 53-89.
Fraser J.A., Biousse V., Newman N.J. The neuro-ophthalmology оf mitochondrial disease. Surv. Ophthalmol. 2010; 55 (4): 299-334.
Khanakova NA, Sheremet NL, Loginova AN, Chukhrova AL, Poliakov AV. Hereditary optic neuropathies: clinical and molecular genetic characteristics. Vestnik oftal'mologii. 2013;129(6):82-87. Review. (In Russ.).
Barboni P., Savini G., Valentino M.L., La Morgia C., Bellusci C., De Negri A.M., Sadun F., Carta A., Carbonelli M., Sadun A.A., Carelli V. Leber's hereditary optic neuropathy with childhood onset. Invest. Ophthalmol. Vis. Sci. 2006; 47 (12): 5303-5309.
mati-Bonneau P., Milea D., Bonneau D., Chevrollier A., Ferre M., Guillet V., Gueguen N., Loiseau D., de Crescenzo M.A., Verny C., Procaccio V., Lenaers G., Reynier P. OPA1-associated disorders: phenotypes and pathophysiology. Int. J. Biochem. Cell. Biol. 2009; 41: 1855-1865.
Nochez Y., Arsene S., Gueguen N., Chevrollier A., Ferre M., Guillet V., Desquiret V., Toutain A., Bonneau D., Procaccio V., mati-Bonneau P., Pisella P.J., Reynier P. Acute and late-onset optic atrophy due to a novel OPA1 mutation leading to a mitochondrial coupling defect. Mol. Vis. 2009; 15; 598-608.
Cornille K., Milea D., mati-Bonneau P., Procaccio V., Zazoun L., Guillet V., El A.G., Delettre C., Gueguen N., Loiseau D., Muller A., Ferre M., Chevrollier A., Wallace D.C., Bonneau D., Hamel C., Reynier P., Lenaers G. Reversible optic neuropathy with OPA1 exon 5b mutation. Ann. Neurol. 2008; 63: 667-671.
Avetisov S.E., Sheremet N.L., Fomin A.V., Galoian N.S., Khanakova N.A., Zhorzholadze N.V., Loginova A.N., Chukhrova A.L., Poliakov A.V. Morphological changes in retina and optic nerve head in patients with Leber's hereditary optic neuropathy. Vestnik oftal'mologii. 2014; 130(1): 4-8. (In Russ.)
Pearce S., Nezich C.L., Spinazzola A. Mitochondrial diseases: Translation matters. Mol. Cell. Neurosci. 2013; 55: 1-12.
Maresca A., Morgia C., Caporali L., Valentino M.L., Carelli V. The optic nerve: a "mito-window" on mitochondrial neurodegeneration. Mol. Cell. Neurosci. 2012; 55: 62-76.
Baracca A., Solaini G., Sgarbi G., Lenaz G., Baruzzi A., Schapira A.H., Martinuzzi A., Carelli V. Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch. Neurol. 2005; 62 (5): 730-736.
Chevrollier A., Guillet V., Loiseau D., Gueguen N., de Crescenzo M.A., Verny C., Ferre M., Dollfus H., Odent S., Milea D., Goizet C., Amati-Bonneau P., Procaccio V., Bonneau D., Reynier P. Hereditary Optic Neuropathies Share a Common Mitochondrial Coupling Defect. Ann. Neurol. 2008; 63: 794-798.
Zanna C., Ghelli A., Porcelli A.M., Karbowski M., Youle R.J., Schimpf S., Wissinger B., Pinti M., Cossarizza A., Vidoni S., Valentino M.L., Rugolo M., Carelli V. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain. 2008; 131 (Pt 2): 352-367. doi: 10.1093/brain/awm335.
Lodi R., Tonon C., Valentino M.L., Manners D., Testa C., Malucelli E., La Morgia C., Barboni P., Carbonelli M., Schimpf S., Wissinger B., Zeviani M., Baruzzi A., Liguori R., Barbiroli B., Carelli V. Defective mitochondrial adenosine triphosphate production in skeletal muscle from patients with dominant optic atrophy due to OPA1 mutations. Arch. Neurol. 2011; 68 (1): 67-73. doi: 10.1001/archneurol.2010.228.
Robinson B.H., Petrova-Benedict R., Buncic J.R., Wallace D.C. Nonviability of Cells with Oxidative Defects in Galactose Medium: A Screening Test for Affected Patient Fibroblasts. Biochem. Med. Metab. Biol. 1992; 48: 122-126.
Benard G., Faustin B., Passerieux E., Galinier A., Rocher C., Bellance N., Delage J.-P., Casteilla L., Letellier T., Rossignol R. Physiological diversity of mitochondrial oxidative phosphorylation. Am. J. Physiol. Cell. Physiol. 2006; 291: 1172-1182.
Handy D.E., Loscalzo J. Redox regulation of mitochondrial function. Antioxid. Redox. Signal. 2012; 16 (11): 1323-1367. doi: 10.1089/ars.2011.4123. Epub 2012 Feb 3. Review.
Reed T.T. Lipid peroxidation and neurodegenerative disease. Free Radic. Biol. Med. 2011; 51 (7): 1302-1319. doi: 10.1016/j.freeradbiomed.2011.06.027. Epub 2011 Jun 30. Review.
Cordeiro M.F., Guo L., Coxon K.M., Duggan J., Nizari S., Normando E.M., Sensi S.L., Sillito A.M., Fitzke F.W., Salt T.E., Moss S.E. Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis. 2010; 1: e3. doi: 10.1038/cddis.2009.3.
Newman N.J. Treatment of hereditary optic neuropathies. Nat. Rev. Neurol. 2012; 8 (10): 545-556.
Huang C.C., Kuo H.C., Chu C.C., Kao L.Y. Rapid visual recovery after coenzyme Q10 treatment of Leber hereditary optic neuropathy. J. Neuroophthalmol. 2002; 22: 66.
Carelli V., La Morgia C., Valentino M.L., Rizzo G., Carbonelli M., De Negri A.M. et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain. 2011; 134: e188.
Klopstok Т., Yu-Wai-Man P., Dimitriadis K., Rouleau J., Heck S., Bailie M. et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011; 134: 2677-2686.
Sharkawi E., Oleszczuk J.D., Holder G.E., Raina J. Clinical and electrophysiological recovery in Leber hereditary optic neuropathy with G3460A mutation. Doc. Ophthalmol. 2012; 125: 71-74.
Kerr D.S. Review of clinical trials for mitochondrial disorders: 1997-2012. Neurotherapeutics. 2013; 10: 307-319.
Acaroğlu G., Kansu T., Doğulu C. Visual recovery patterns in children with Leber's hereditary optic neuropathy. Int. Ophthalmol. 2001; 24: 349-355.